<b>Advances and Problems in Preclinical Models for Childhood Cancer</b> Microblogging today has gotten an acclaimed specific instrument among Neuroblastoma is a sympathetic nervous system disease in children and is the most prevalent solid tumor in childhood, accounting for 15 of all pediatric oncology deaths. Nearly 80 of patients with this clinically active condition do not react to current treatments in the long run. The precise portrayal of tumor biology and diversity is the key obstacle in the discovery and evaluation of novel agents for pediatric drug growth. In addition to this restriction, the low prevalence of neuroblastoma renders it difficult to enroll qualifying patients for early phase clinical trials, emphasizing the importance of thorough preclinical studies to ensure that the right drugs are chosen. To address these issues, researchers need new preclinical models, technologies, and principles. Tissue engineering provides appealing methods for developing three dimensional 3D cell models utilizing different biomaterials and manufacturing techniques that replicate the geometry, dynamics, heterogeneity, metabolic gradients, and cell connectivity of the native tumor microenvironment. We address existing laboratory models and evaluate their ability to reflect the systemic organization and physiological conditions of the human body, as well as current and emerging strategies to recapitulate the tumor niche utilizing tissue engineered platforms in this study. Finally, we ll talk about how innovative 3Din vitroculture systems might be used to answer unanswered questions in neuroblastoma biology. Neuroblastoma, Tissue engineering, childhood cancer 762-765 Issue-4 Volume-5 V. Sah